INMB Q3 2024 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$12M

Net Income

-$12M

EPS (Diluted)

$-0.60

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$53M

Total Liabilities

$14M

Stockholders' Equity

$39M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$43,000	-100.0%
Gross Profit	$0	$43,000	-100.0%
Operating Income	-$12M	-$9M	-44.1%
Net Income	-$12M	-$9M	-41.2%